Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

Delayed Data
As of 4:02pm ET
 +0.18 / +12.24%
Today’s Change
Today|||52-Week Range

Stock Price Forecast

The 6 analysts offering 12-month price forecasts for Adaptimmune Therapeutics PLC have a median target of 6.00, with a high estimate of 9.00 and a low estimate of 2.00. The median estimate represents a +263.64% increase from the last price of 1.65.

Analyst Recommendations

The current consensus among 8 polled investment analysts is to Hold stock in Adaptimmune Therapeutics PLC. This rating has held steady since August, when it was unchanged from a Hold rating.Move your mouse over past
months for detail


Earnings and Sales Forecasts

Current Quarter

Earnings per Share
Reporting Date
Aug 04

Earnings per Share

Move your mouse over a quarter or year to see how estimates have changed over time.

Growthquarterly -480.00%
Growthannually -610.59%


Growthquarterly 83.82%
Growthannually 270.92%
Key to the earnings and sales forecast charts.